Thanks to a $750,000 grant from the Cleveland Foundation, Cleveland Clinic has established a chair for preventive cardiology.
Dr. Stanley Hazen — who holds several titles with the Clinic, including director for the Center for Cardiovascular Diagnostics and Prevention — has been chosen to hold the chair, according to a statement from the Clinic.
Hazen is no stranger to the medical innovation community. His research led to the invention of a biomarker test called CardioMPO that is the linchpin of a panel of heart inflammation tests for Cleveland HeartLab, one of the most promising companies in a stable of Cleveland Clinic spinoffs.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
In addition to royalty payments from his HeartLab invention, Hazen receives royalties from Abbott Laboratories, Siemens and Frantz Biomarkers. He’s also been awarded stock by Pfizer for his work as a consultant with the drug developer.
Hazen’s specialty research interests include atherosclerosis, cardiac rehabilitation and cardiovascular risk evaluation, according to his bio on the Clinic’s site.
